CN Patent

CN113546052A — 治疗人免疫缺陷病毒的治疗组合物

Assigned to Gilead Sciences Inc · Expires 2021-10-26 · 5y expired

What this patent protects

本申请涉及用于治疗人免疫缺陷病毒感染的治疗组合物。具体地，本申请提供了一种固体口服剂型，其包含式I化合物或其药学上可接受的盐、替诺福韦艾拉酚胺或其药学上可接受的盐以及恩曲他滨或其药学上可接受的盐。

USPTO Abstract

本申请涉及用于治疗人免疫缺陷病毒感染的治疗组合物。具体地，本申请提供了一种固体口服剂型，其包含式I化合物或其药学上可接受的盐、替诺福韦艾拉酚胺或其药学上可接受的盐以及恩曲他滨或其药学上可接受的盐。

Drugs covered by this patent

bictegravir-sodium (BICTEGRAVIR SODIUM)

Patent Metadata

Patent number: CN113546052A
Jurisdiction: CN
Classification: —
Expires: 2021-10-26
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.